Adagio Medical Receives FDA IDE Approval for Next-Generation vCLAS™ Ventricular Ablation System Trial

Adagio Medical Holdings, Inc. announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA). This approval allows the company to expand its FULCRUM-VT trial to evaluate the safety and effectiveness of its next-generation vCLAS Ultra-Low Temperature Ablation (ULTA) Ventricular Ablation System. The system is designed to offer faster, more efficient ablation with improved usability for treating Sustained Monomorphic Ventricular Tachycardia (SMVT), addressing a challenging cardiac arrhythmia. This regulatory milestone is crucial for advancing Adagio's pipeline and potentially expanding its market presence in cardiac ablation technologies.